Business Context and Reporting Period
Foghorn Therapeutics Inc. filed a Form 8-K dated December 29, 2023, under Item 5.02(b) to report the planned departure of its Chief Financial Officer. The filing was signed and submitted on January 3, 2024.
Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
Material Changes
- Allan Reine, M.D. notified the company on December 29, 2023, that he would resign as Chief Financial Officer effective January 16, 2024.
- Dr. Reine stated that his resignation was to pursue other opportunities and was not due to any disagreement with the company regarding its operations, policies, practices, financial controls, or audit procedures.
- The company had commenced a search for his replacement as of the filing.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no financial guidance or operating outlook. The CFO transition may create management continuity and financial-reporting execution considerations until a replacement is appointed, although the filing does not identify any related deficiency or dispute.
Investor Verification Items
- Verify the effective date of Dr. Reine’s departure: January 16, 2024.
- Monitor the appointment, qualifications, and transition arrangements for the successor CFO.
- Review subsequent filings for any changes to financial controls, audit procedures, reporting timelines, or related compensation arrangements.
- Review Exhibit 99.1, the January 3, 2024 press release, for additional management commentary.